Stealth BioTherapeutics Corp (NASDAQ: MITO) is -42.51% lower on its value in year-to-date trading and has touched a low of $0.90 and a high of $14.41 in the current 52-week trading range. The MITO stock was last observed hovering at around $1.87 in the last trading session, with the day’s gains setting it 0.17% off its average median price target of $5.00 for the next 12 months. It is also 79.6% off the consensus price target high of $10.00 offered by 7 analysts, but current levels are -36.0% lower than the price target low of $1.50 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $2.04, the stock is 1.96% and 7.95% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.07 million and changing 8.85% at the moment leaves the stock -51.04% off its SMA200. MITO registered -85.23% loss for a year compared to 6-month loss of -57.88%. The firm has a 50-day simple moving average (SMA 50) of $1.9919 and a 200-day simple moving average (SMA200) of $2.7612.
The stock witnessed a -11.60% gain in the last 1 month and extending the period to 3 months gives it a 34.83%, and is -4.86% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.67% over the week and 7.99% over the month.
Stealth BioTherapeutics Corp (MITO) has around 73 employees, a market worth around $64.51M and $21.10M in sales. Distance from 52-week low is 126.62% and -85.84% from its 52-week high. The company has generated returns on investments over the last 12 months (-205.50%).
Stealth BioTherapeutics Corp (MITO) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Stealth BioTherapeutics Corp (MITO) is a “Overweight”. 7 analysts offering their recommendations for the stock have an average rating of 2.40, where 3 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Stealth BioTherapeutics Corp is expected to release its quarterly report on 08/12/2020 and quarterly earnings per share for the current quarter are estimated at -$0.02.The EPS is expected to grow by 25.80% this year, but quarterly earnings will post -99.70% year-over-year.
Stealth BioTherapeutics Corp (MITO) Top Institutional Holders
6 institutions hold shares in Stealth BioTherapeutics Corp (MITO), with institutional investors hold 14.03% of the company’s shares. The shares outstanding are 36.39M, and float is at 5.73M with Short Float at 0.20%. Institutions hold 14.03% of the Float.
The top institutional shareholder in the company is Prosight Management, LP with over 0.34 million shares valued at $0.42 million. The investor’s holdings represent 0.96% of the MITO Shares outstanding. As of Mar 30, 2020, the second largest holder is Brown Brothers Harriman & Co with 0.17 million shares valued at $0.22 million to account for 0.50% of the shares outstanding. The other top investors are Renaissance Technologies, LLC which holds 0.13 million shares representing 0.36% and valued at over $0.16 million, while Ikarian Capital, LLC holds 0.11% of the shares totaling 37597.0 with a market value of $46620.0.